0590

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner of Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

Bernastette B. Fahry Bernadette B. Fahry

<u>June 17, 2002</u> Date

Att. Docket No. REG 780D

HECEIVED JUL I 0 2002 \$ 0 0 0



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

: Murphy, et al.

USSN

: 10/076,840

Filed

: February 15, 2002

For

METHODS OF MODIFYING

EUKARYOTIC CELLS

Examiner

Not Yet Known

Group

Not Yet Known

June 17, 2002

Commissioner for Patents U.S. Patent and Trademark Office Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.§1.97(c) AND 1.98

SIR:

Submitted herewith is PTO Form 1449 to make of record those references of which Applicant is aware that may be pertinent to an examination of the captioned patent application on the merits. Copies of the listed references without an asterisk are enclosed, Copies of references with an asterisk may be found in parent case USSN 09/732,234.

Att. Dkt. No. REG 780D USSN 10/076,840 Transmittal of IDS Page 2



No fee is deemed necessary for filing this paper. However, if any fee is required, the Commissioner is hereby authorized to charge any such fee to Deposit Account No. 18-0650.

Respectfully submitted,

Linda O. Palladino Reg. No. 45,636

Patent Agent for Applicants

Gail M. Kempler Reg. No. 32,143

Joseph M. Sorrentino

Reg. No. 32,598

Laura J. Fischer

Reg. No. 50,420

Attorneys for Applicants

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400

JUL 1 0 2002

PPORM PTO-1449

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att Docket No.:

REG 780D

USSN

10/076,840

Applicant

Murphy, et al.

Date Filed

February 15, 2002

For

METHODS OF MODIFYING

EUKARYOTIC CELLS

Examiner

Not Yet Known

Group Art Unit

Not Yet Known

June 17, 2002

U.S. PATENT DOCUMENTS


Examiner <u>Initials</u>	Patent <u>Number</u>	Patent <u>Date</u>	<u>Name</u>	Class/ Subclass	Filing <u>Date</u>
	* <u>5,789,215</u>	08/04/98	Berns, et al.		
	* <u>5,436,149</u>	0 <u>7/25/95</u>	Barnes, W.		

FOREIGN PATENT DOCUMENTS

Examiner	Document			Class/	Transla	ation
<u>Initials</u>	Number	<u>Date</u>	Country	<u>Subclass</u>	<u>Yes</u>	<u>No</u>
	WO94/02602	02/03/94	<u>PCT</u>	<u>C12N 15/0</u>	0	

OTHER DOCUMENTS

Examiner <u>Initials</u>	
	*NATURE, Vol. 317, 1985, Smithies, O., et al., "Insertion of
	DNA sequences into the human chromosomal ß-globin
	locus by homologous recombination," pp. 230-234.
	*CELL, Vol. 51, 1987, Thomas, K.R., and Capecchi, M.R., "Site-
	Directed Mutagenesis by Gene Targeting in Mouse Embryo-
	Derived Stem Cells," pp. 503-512.
	*PROC. NATL. ACAD. SCI. USA, Vol. 86, 1989, Koller, B.H., et
	al., "Germ-line transmission of a planned alteration made in
	a hypoxanthine phosphoribosyltransferase gene by
	homologous recombination in embryonic stem cells," pp. 8927-
	8931.
	*SCIENCE, Vol. 254, 1991, Kuhn, R., et al., "Generation and
	Analysis of Interleukin-4 Deficient Mice," pp. 707-710
	*NATURE, Vol. 346, 1990, Thomas, K.R., and Capecchi, M.R.,
	"Targeted disruption of the murine int-1 proto-oncogene
	resulting in severe abnormalities in midbrain and cerebellar
	development," pp. 847-850.
	*SCIENCE, Vol. 246, 1989, Scwartzberg, P.L., et al., "Germ-line
	Transmission of c-abl Mutation produced by Targeted Gene
	Disruption in ES Cells," pp. 799-803.



Murphy, et al. *MOLECULAR AND CELLULAR BIOLOGY, Vol. 12 No. 8, 1992, Deng, C., and Capecchi, M.R., "Reexamination of Gene Targeting Frequency as a Function of the Extent of Homolgy between the Targeting Vector and the Target Locus," pp. 3365 *-*3371. *NATURE GENETICS, Vol. 20, 1998, Zhang, Y., et al., "A new logic for DNA engineering using recombination in Escherichia coli, "pp. 123-128. *NUCLEIC ACIDS RESEARCH, Vol. 27, 1999, Angrand, P., et al, "Simplified generation of targeting constructs using ET recombination," pp. 16(e). *NUCLEIC ACIDS RESEARCH, Vol. 27, 1999, Muyrers, J.P., et al., "Rapid modification of bacterial artificial chromosomes by ET-recombination," pp. 1555-1557. *GENE THERAPY, Vol. 6, 1999, Narayanan, K. et al., "Efficient and precise engineering of a 200kb ß-globin human/bacterial artificial chromosome in E. coli DH10B using an inducible homologous recombination system," pp. 442-447. *GENOMICS, Vol. 64, 1999, Hill, F., et al., "BAC Trimming: Minimizing Clone Overlaps," pp. 111-113. *NATURE BIOTECHNOLOGY, Vol. 15, 1997, Yang, X, et al., "Homologous recombination based modification in Escherichia coli and germline transmission in transgenic

Reg 780D

USSN 10/076,840

Information Disclosure Statement


mice of a bacterial artificial chromosome," pp. 859-865.

Murphy, et al. *PROC. NATL. ACAD. SCI. USA, Vol. 97, 2000, Yu, D., et al., "An efficient recombination system for chromosome engineering in Escherichia coli," pp. 5978-5983. *PROC. NATL. ACAD. SCI. USA, Vol. 91, 1994, Hall, S. D, and Kolodner, R.D., "Homologous pairing and strand exchange promoted by the Escherichia coli RecT protein," pp. 3205-3209. *GENE, Vol. 138, 1994, Kusano, K., et al., "Involvement of RecE and RectT annealing protein in DNA double-stranded break repair by homologous recombination," pp. 17-25. *SCIENCE, Vol. 277, 1997, Kovall, R, and Matthews, B.W., "Toroidal Structure of λ-Exonuclease," pp. 1824-1827. *COLD SPRINGS HARB SYMP QUANT BIOL, Vol. 49, 1984, Clark, A.J., et al., "Genes of the RecE and RecF Pathways of Conjugational Recombination in Escherichia coli, " pp. 453-462. *J BIOL CHEM, Vol. 273, 1998, Noirot, P., and Kolodner, R.D., "DNA Strand Invasion Promoted by Escherichia coli RecT Protein," pp. 12274-80. *J MOL BIOL, Vol. 254, 1995, Thresher, et al., "Electron Microscopic Visualization of RecT Protein and its Complexes with DNA,"pp. 364-371. *MOLECULAR MICROBIOLOGY, Vol. 11, 1994, Kolodner, et al., "Homologous pairing proteins encoded by the Escherichia coli recE and recT genes," p. 23-30.


Reg 780D

USSN 10/076,840

Information Disclosure Statement



Reg 780D



*AMERICAN JOURNAL OF PATHOLOGY, Vol. 145, 1994, Houldsworth, J, and Chaganti, R.S.K., "Comparative Genomic Hybridization: An Overview," p. 1253-1260. *NATURE GENETICS, Vol. 19, 1998, Lizardi, P.M., et al., "Mutation detection and single-molecule counting using isothermal rolling-circle amplification," pp. 225-232. *NUCLEIC ACIDS RESEARCH, Vol. 27, 1999, Mitra, R.D., and Church, G.M., "In situ localized amplification and contact replication of many individual DNA molecules," pp. e34. NUCLEIC ACIDS RESEARCH, Vol. 25, No. 14, 1997, Bethke, Bruce And Sauer, Brian, "Segmental genomic replacement by Cre-Mediated recombination: genotoxic stress activation of the p53 promoter in single-copy transformants", pp. 2828-2834. MOLECULAR IMMUNOLOGY, Vol. 33, No. 17/18, 1996, Shigeharu Fujieda, et al., "Direct Evidence That γ1 And γ3 Switching In Human B Cells Is Interleukin-10 Dependent", pp. <u>1335-1343.</u> EUR. J. IMMUNOL., Vol. 28, 1998, Brain B. Haines and Peter H. Brodeur, "Accessibility changes across the mouse Igh-V locus during B cell development", pp. 4228-4235 NATURE GENETICS, Vol. 20, 1998, Herault, Yann, et al., "Engineering chromosomes in mice through targeted meiotic recombination (TAMERE)", pp. 381-384.

Reg 780D

USSN 10/076,840

Murphy, et al.

Information Disclosure Statement

Murphy, et al. NUCLEIC ACIDS RESEARCH, Vol. 14, No. 5, 1986, Hoess, Ronald H., et al., "The role of the *loxP* spacer region in PI site-specific recombination", pp. 2287-2300. EUR. J. IMMUNOL, Vol. 6, 1976, G. Kohler and C Milstein, "Derivation of specific antibody-producing tissue cultue and tumor lines by cell fusion", pp. 511-519. ANALYTICAL BIOCHEMISTRY, Vol. 290, 2001, Andreas F. Kolb, "Selection-Marker-Free Modification of the Murine β-Casein Gene Using a *lox*2722 Site", pp. 260-271. CURRENT OPINION IN BIOTECHNOLOGY, Vol. 9, 1998, Yolanda S. Lie and Christos J. Petropoulos, "Advances in quantitative PCR technology: 5' nuclease assays", pp. 43-48. THE JOURNAL OF IMMUNOLOGY, 1998, Ong, Jane, et al., "3' IgH Enhancer Elements Shift Synergistic Interactions During B Cell Development", pp. 4896-4903. EUR. J. IMMUNOL., Vol. 30, 2000, Pan, Qiang, et al., "Regulation of the promoter for human immunoglobulin γ3 germ-line transcription and its interaction with the $3'\alpha$ enhancer", pp. <u>1019-1029.</u> MOLECULAR AND CELLULAR BIOLOGY, Vol. 19, No. 10, October 1999, Ronai, Diana, et al., "Variegated Expression of the Endogenous Immunoglobulin Heavy-Chain Gene in the Absence of the Intronic Locus Control Region", pp. 7031-7040.

Reg 780D

USSN 10/076,840

Information Disclosure Statement

	PNAS, Vol. 97, No. 2, January 18, 2000, Tomizuka, Kazuma, et
	al., "Double trans-chromosomic mice: Maintenance of two
	individual human chromosome fragments containing Ig
	heavy and κ loci and expression of fully human antibodies",
	pp. 722-727.
	FACULTY OF BIOLOGY, University of Konstanz, Germany, 1999,
	Willers, Jörg, et al., "Apparent Trans-Chromosomal Antibody
	Class Switch in Mice Bearing an Igh $^{\alpha}$ μ -chain Transgene on an
	Igh ^b Genetic Background", pp. 150-164.
	NATURE BIOTECHNOLOGY, Vol. 15, September 1997, Yang,
	Xiangdong W., et al., "Homologous recombination based
	modification in Esherichia coli and germline transmission in
	transgenic mice of a bacterial artificial chromsome", (sic) pp. 859-
	865

^{*} Items with an asterisk were submitted in parent applicatin USSN 09/732,234 on June 18, 2001.

EXAMINER CONSIDERED

DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

Ву:

Linda O. Palladino Reg. No. 45,636

Patent Agent for Applicants

Gail M. Kempler Reg. No. 32,143

Joseph M. Sorrentino

Reg. No. 32,598 Laura J. Fischer Reg. No. 50,420

Attorneys for Applicants

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591

(914) 345-7400